

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 0233)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The Board of the Company is pleased to announce that:

1. Dr. Lam, Lee G. has been appointed as an independent non-executive director, a member of nomination committee, chairman of audit committee and remuneration committee of the Company with effect from 12 September 2014.
2. Mr. Yang Chun Bao has been appointed as an independent non-executive director, a member of nomination committee, audit committee and remuneration committee of the Company with effect from 12 September 2014.

The board of directors (the “Board”) of Mingyuan Medicare Development Company Limited (the “Company”) is pleased to announce that (1) Dr. Lam, Lee G. (“Dr. Lam”) has been appointed as an independent non-executive director, a member of nomination committee, chairman of audit committee and remuneration committee with effect from 12 September 2014; (2) Mr. Yang Chun Bao (“Mr. Yang”) has been appointed as an independent non-executive director, a member of nomination committee, audit committee and remuneration committee of the Company with effect from 12 September 2014.

Brief Profile of Dr. Lam

Dr. Lam, aged 55, is currently Chairman - Indochina, Myanmar and Thailand (and formerly Chairman - Hong Kong), and Senior Adviser - Asia, of Macquarie Capital (Hong Kong) Limited.

Dr. Lam holds a Bachelor of Science in Sciences and Mathematics, a Master of Science in Systems Science, and a Master of Business Administration Degree, all from the University of Ottawa in Canada, a Post-graduate Diploma in Public Administration from Carleton University in Canada, a Post-graduate Diploma in English and Hong Kong Law and a Bachelor of Law (Hons) from Manchester Metropolitan University in the United Kingdom, a PCLL in law from the City University of Hong Kong, a Certificate in Professional Accountancy from the Chinese University of Hong Kong SCS, a LLM in law from the

University of Wolverhampton in the United Kingdom, a Master of Public Administration and a Doctor of Philosophy Degree from the University of Hong Kong.

Dr. Lam has over 30 years of international experience in general management, management consulting, corporate governance, direct investment, investment banking and fund management across the telecommunications, media and technology (TMT), consumer/healthcare, infrastructure/real estates, resources/energy and financial services sectors, and he also serves on the board of a number of publicly-listed companies and investment funds in the Asia Pacific region. Having served as a Part-time Member of the Central Policy Unit of the Government of the Hong Kong Special Administrative Region for two terms and the Legal Aid Services Council, Dr. Lam is a Member of the Jilin Province Committee (and formerly a Specially-invited Member of the Zhejiang Province Committee) of the Chinese People's Political Consultative Conference, a Vice Chairman of Liaoning Chinese Overseas Friendship Association, a Member of the New Business Committee of the Financial Services Development Council (FSDC), a Member of the Derivatives Market Consultative Panel of Hong Kong Exchanges and Clearing Limited (HKEx), a Member of the Hong Kong Institute of Bankers, a Member of the World Presidents' Organization, a Member of the Chief Executives Organization, a Fellow of the Hong Kong Institute of Directors and the Hong Kong Institute of Arbitrators, an Accredited Mediator of the Centre for Effective Dispute Resolution (CEDR), a Member of the General Committee and the Corporate Governance Committee of the Chamber of Hong Kong Listed Companies, a Board Member of the Australian Chamber of Commerce in Hong Kong and Macau, a founding Board Member and the Honorary Treasurer of the Hong Kong-Vietnam Chamber of Commerce, a founding Member of the Hong Kong-Korea Business Council, a Vice President of the Hong Kong Real Property Federation, and Chairman of Monte Jade Science and Technology Association of Hong Kong.

Dr. Lam is currently an independent/non-executive director of the following companies which shares are quoted on the stated stock exchange:-

On the Hong Kong Stock Exchange:

CSI Properties Limited (Stock Code: 497), Far East Holdings International Limited (Stock Code: 36), Glorious Sun Enterprises Limited (Stock Code: 393), Heng Fai Enterprises Limited (Stock Code: 185), Hutchison Harbour Ring Limited (Stock Code: 715), Imagi International Holdings Limited (Stock Code: 585), Mei Ah Entertainment Group Limited (Stock Code: 391), Sunwah Kingsway Capital Holdings Limited (Stock Code: 188), Vongroup Limited (Stock Code: 318), Ruifeng Petroleum Chemical Holdings Limited (Stock Code: 8096);

On the Stock Exchange of Singapore:

Rowsley Limited. (Stock Code: A50) and Asia-Pacific Strategic Investments Limited (Stock Code: 5RA), Top Global Limited (Stock Code: 519);

On the Toronto Stock Exchange:

Sunwah International Limited (Stock Code: TSX SWH);

On the Stuttgart Stock Exchange:

Vietnam Equity Holding (Stock Code: 3MS), Vietnam Property Holding (Stock Code: 3MT); and

On the Australian Stock Exchange:

Coalbank Limited (Stock Code: ASX CBQ).

Within the past three years Dr. Lam was an independent non-executive director of the following companies which shares are quoted on the stated stock exchange:-

On the Hong Kong Stock Exchange:

China Communication Telecom Services Company Limited (Stock Code: 8206), Wai Chun Mining Industry Group Co. Ltd. (Stock Code: 660), Mingyuan Medicare Development Company Limited (Stock Code: 233);

On the Singapore Stock Exchange:

Next-Generation Satellite Communications Limited (Stock Code: B07);

On the Malaysian Stock Exchange:

TMC Life Sciences Berhad (Stock Code: MYX0101); and

On the NASDAQ Exchange:

CDC Software Corporation (Stock Code: CDCS).

Dr. Lam does not enter into a service contract with the Company. Dr. Lam is not appointed for a specific term but is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws of the Company. The emolument for Dr. Lam is determined by the Board with reference to Dr. Lam's responsibilities and duties within the Company.

Dr. Lam does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company. As at the date of this announcement, Dr. Lam did not have any interest in shares of the Company within the meaning of Part XV of the Securities and Future Ordinance.

Save as disclosed herein, in relation to the appointment of Dr. Lam as an independent non-executive director of the Company, there is no information which is discloseable nor is/was he involved in any of the matters required to be disclosed pursuant to any of the requirements of the provisions under paragraphs 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter which needs to be brought to the attention of the shareholders of the Company.

Brief Profile of Mr. Yang

Mr. Yang Chun Bao (楊春寶), aged 58, has more than 31 years of experience in finance and accounting. Mr Yang was admitted as a certified public accountant and he joined Shanghai Huashen Certified Public Accountants Ltd. (上海華申會計師事務所有限公司) in November 1973 and became a deputy supervisor

(副主任) in June 2005. In July 2011, he was promoted to be the accountant-in-charge (主任會計師) of the firm. Mr Yang was conferred a degree of Master of Science in Business Administration by Madonna University at Livonia, Michigan, the USA in December 1999.

Mr. Yang is currently an independent non-executive director of Shanghai Qingpu Fire-Fighting Equipment Co., Ltd. which is listed on The Stock Exchange of Hong Kong Limited (stock code: 8115).

Mr. Yang does not enter into a service contract with the Company. Mr. Yang is not appointed for a specific term but is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws of the Company. The director's fee for Mr. Yang is HK\$120,000 per annum. The emolument for Mr. Yang is determined by the Board with reference to Mr. Yang's responsibilities and duties within the Company.

Mr. Yang does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company. As at the date of this announcement, Mr. Yang did not have any interest in shares of the Company within the meaning of Part XV of the Securities and Future Ordinance.

Save as disclosed herein, in relation to the appointment of Mr. Yang as an independent non-executive director of the Company, there is no information which is discloseable nor is/was he involved in any of the matters required to be disclosed pursuant to any of the requirements of the provisions under paragraphs 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter which needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend a warm welcome to Dr. Lam and Mr. Yang.

By the Order of the Board

Yao Yuan

Chairman & CEO

Hong Kong, 12 September 2014

As at the date of this announcement, the executive directors are Mr. Yao Yuan (Chairman & CEO), Mr. Zhao Chao, and Mr. Zhou Li Qun; non-executive director is Mr. Yu Ti Jun; the independent non-executive director are Dr. Lam, Lee G., Mr. Yang Chun Bao and Mr. Tang Yan Qin.

** For identification purposes only*